For over a half century, molecular modeling methods have been applied to small molecule discovery, with many notable successes. Focus is now increasingly being directed to proteins as therapeutics or synthetic biology tools, and to computational methods that can be applied to design of these valuable proteins. Much of this protein design work has been based solely on predictive approaches derived from first principle physics.
Rosetta, available commercially as Cyrus Bench, has fundamentally changed protein design through the use of a scoring function that reflects a combination of key physical insights from traditional methods and statistical knowledge from the vast accumulation of protein structures solved over the last six decades. This combined approach is very different from all other commercially-available software toolkits, and has leapfrogged other methods for protein modeling.
This has lead to many “firsts” in the field of protein design, including the first fully software-designed proteins, the first designed proteins with biochemical characteristics as good as or better than a therapeutic antibody or enzyme, and the first designed proteins in human clinical trials (Tocagen and PVP Bio).
These Rosetta tools are now accessible through Cyrus Bench, and are helping Cyrus customers advance their discovery programs into pre-clinical and clinical trials.
Our mission is to transform therapeutics and synthetic biology discovery, accelerating new treatments and protein-based materials to market, and creating entirely new treatments computationally that are difficult or impossible to identify using conventional means.